5 years ago10 views
Complete report is available @ http://www.rnrmarketresearch.com/pharmapoint-seasonal-influenza-vaccines-global-drug-forecast-and-market-analysis-to-2022-event-driven-update-market-report.html .
Seasonal Influenza is a respiratory infection caused by influenza virus that results in mild to severe symptoms, such as fever, cold and cough. The market is heavily driven by the sales of prophylactic vaccine treatments to prevent infection. Currently, trivalent intramuscular vaccines such as Sanofi’s Fluzone and Vaxigrip, GlaxoSmithKline’s Fluarix and FluLaval and Novartis’ Fluvirin garner the majority stake of the market. However, with the entrance of vaccines with novel routes of administration, such as AstraZeneca’s intranasal FluMist and Sanofi’s Fluzone IntraDermal, Reseacher projects a dramatic shift favoring the adoption of such vaccines over the traditional intramuscular vaccines. Researcher also anticipates that manufacturers that launch quadrivalent formulations will steal market share, patient share, and revenue from the trivalent influenza vaccines currently available.